Market closedNon-fractional
Outlook Therapeutics/OTLK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Outlook Therapeutics
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Ticker
OTLK
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Iselin, United States
Employees
24
Website
www.outlooktherapeutics.com
OTLK Metrics
BasicAdvanced
$195M
Market cap
-
P/E ratio
-$11.98
EPS
0.28
Beta
-
Dividend rate
Price and volume
Market cap
$195M
Beta
0.28
Financial strength
Current ratio
1.069
Quick ratio
0.873
Total debt to equity
-33.333
Interest coverage (TTM)
-27.28%
Management effectiveness
Return on assets (TTM)
-66.19%
Return on equity (TTM)
257.19%
Valuation
Price to book
-1.39
Price to tangible book (TTM)
-1.39
Price to free cash flow (TTM)
-1.901
Growth
Earnings per share change (TTM)
142.25%
3-year earnings per share growth (CAGR)
21.47%
What the Analysts think about OTLK
Analyst Ratings
Majority rating from 7 analysts.
OTLK Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
NaN%
Net income
-$114M
928.83%
Profit margin
0.00%
NaN%
OTLK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$1.60
-$1.00
-$0.80
-$8.01
-
Expected
-$1.03
-$1.18
-$1.00
-$0.85
-$1.02
Surprise
55.56%
-14.89%
-20.00%
842.35%
-
OTLK News
AllArticlesVideos
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
MarketBeat·2 weeks ago
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
GlobeNewsWire·3 weeks ago
Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
MarketBeat·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Outlook Therapeutics stock?
Outlook Therapeutics (OTLK) has a market cap of $195M as of July 27, 2024.
What is the P/E ratio for Outlook Therapeutics stock?
The price to earnings (P/E) ratio for Outlook Therapeutics (OTLK) stock is 0 as of July 27, 2024.
Does Outlook Therapeutics stock pay dividends?
No, Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Outlook Therapeutics dividend payment date?
Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders.
What is the beta indicator for Outlook Therapeutics?
Outlook Therapeutics (OTLK) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Outlook Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.